prostate hyperplasia

Dapoxetine (Dapoxetina) is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation.

Dapoxetine hydrochloride (LY-210448 hydrochloride) is a selectivity short-acting serotonin reuptake inhibitor, used for the therapy of premature ejaculation.

Terazosin hydrochloride (Hytrin) , a selective alpha1-antagonist, can treat the benign prostatic hyperplasia (BPH). It also can lower blood pressure, so it is a drug of choice for patients with prostate enlargement and hypertension. It works on the smooth muscle of the bladder and the blood vessel walls by blocking the function of adrenaline.

Naftopidil (KT-611) (INN, marketed under the brand name Flivas), an antihypertensive medicine, is used as a selective α1-adrenergic receptor antagonist or α-blocker.

Tamsulosin ((R)-(-)-YM12617 free base) is an alpha1A adrenergic receptor antagonist used for the symptomatic treatment of benign prostatic hyperplasia (BPH). It treats difficulty urinating, a common symptom of an enlarged prostate, by relaxing the neck muscles of the bladder and muscle fibers in the prostate itself, easing urination.

Fexapotide (NX-1207 free acid) selectively induces apoptosis to effectively reduce prostate volume at the cellular level and is applicable in the research of lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) [1][2][3].

Naftopidil hydrochloride (BM-15275 hydrochloride) is a selective alpha1-adrenoceptor antagonist with Ki of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-adrenoceptor, α1b-adrenoceptor and α1d-adrenoceptor, respectively. Naftopidil hydrochloride has antiproliferative effects.

Ganoderol B is a natural product isolated from Ganoderma lucidum and an α-glucosidase inhibitor with an IC50 of 119.8 μM, applicable for diabetes research.

Dicentrine is an alkaloid-enriched fraction and the primary alkaloid of the leaves of Ocotea puberula (Lauraceae), a native Brazilian plant traditionally used by Indigenous populations for skin affections, and dicentrine further demonstrates pharmacological activity as an α1-adrenoceptor antagonist in human hyperplastic prostate tissue. Dicentrine has been evaluated using radioligand binding assays with [3H]prazosin and in vitro isometric tension experiments, confirming functional α1-adrenoceptor involvement and supporting therapeutic relevance in disorders associated with prostate hyperplasia.

Fexapotide (NX-1207) TFA selectively induces apoptosis, leading to a reduction in prostate volume at the cellular level. Fexapotide is applicable for research into lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).